NCT03907969 - A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 9, 2019

Primary Completion Date

December 7, 2022

Study Completion Date

December 7, 2022

Conditions

Advanced Malignancies

Interventions

DRUG

AZD7648

Core: AZD7648 will be administered orally

DRUG

PLD

The starting dose of PLD is 40 mg/m\^2, administered by intravenous infusion once every 4 weeks, for a maximum of 6 cycles

Trial Locations (5)

Research Site, Houston

Research Site, New Haven

Research Site, London

Research Site, London

Research Site, Newcastle upon Tyne